A012301

The purpose of this study is to compare low-dose tamoxifen versus standard-of-care endocrine therapy for 5 years to see if the recurrence-free interval is equivalent between groups, among post-menopausal women with early stage, low risk breast cancer. Follow-up continues for up to 10 years.